Metabolic effects of resistant starch type 2

A systematic literature review and meta-analysis of randomized controlled trials

Matthew Snelson, Jessica Jong, Deanna Manolas, Smonda Kok, Audrey Louise, Romi Stern, Nicole J. Kellow

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Published evidence exploring the effects of dietary resistant starch (RS) on human cardiometabolic health is inconsistent. This review aimed to investigate the effect of dietary RS type 2 (RS2) supplementation on body weight, satiety ratings, fasting plasma glucose, glycated hemoglobin (HbA1c), insulin resistance and lipid levels in healthy individuals and those with overweight/obesity, the metabolic syndrome (MetS), prediabetes or type 2 diabetes mellitus (T2DM). Five electronic databases were searched for randomized controlled trials (RCTs) published in English between 1982 and 2018, with trials eligible for inclusion if they reported RCTs involving humans where at least one group consumed ≥ 8 g of RS2 per day and measured body weight, satiety, glucose and/or lipid metabolic outcomes. Twenty-two RCTs involving 670 participants were included. Meta-analyses indicated that RS2 supplementation significantly reduced serum triacylglycerol concentrations (mean difference (MD) = −0.10 mmol/L; 95% CI −0.19, −0.01, P = 0.03) in healthy individuals (n = 269) and reduced body weight (MD = −1.29 kg; 95% CI −2.40, −0.17, P = 0.02) in people with T2DM (n = 90). However, these outcomes were heavily influenced by positive results from a small number of individual studies which contradicted the conclusions of the majority of trials. RS2 had no effects on any other metabolic outcomes. All studies ranged from 1–12 weeks in duration and contained small sample sizes (10–60 participants), and most had an unclear risk of bias. Short-term RS2 supplementation in humans is of limited cardiometabolic benefit.

Original languageEnglish
Article number1833
Number of pages26
JournalNutrients
Volume11
Issue number8
DOIs
Publication statusPublished - 1 Aug 2019

Keywords

  • Dietary fiber
  • Metabolic health
  • Metabolic syndrome
  • Obesity
  • Resistant starch
  • Systematic review
  • Type 2 diabetes

Cite this

@article{fdf27928eb6a4ae7a98ee6b30a8d90ae,
title = "Metabolic effects of resistant starch type 2: A systematic literature review and meta-analysis of randomized controlled trials",
abstract = "Published evidence exploring the effects of dietary resistant starch (RS) on human cardiometabolic health is inconsistent. This review aimed to investigate the effect of dietary RS type 2 (RS2) supplementation on body weight, satiety ratings, fasting plasma glucose, glycated hemoglobin (HbA1c), insulin resistance and lipid levels in healthy individuals and those with overweight/obesity, the metabolic syndrome (MetS), prediabetes or type 2 diabetes mellitus (T2DM). Five electronic databases were searched for randomized controlled trials (RCTs) published in English between 1982 and 2018, with trials eligible for inclusion if they reported RCTs involving humans where at least one group consumed ≥ 8 g of RS2 per day and measured body weight, satiety, glucose and/or lipid metabolic outcomes. Twenty-two RCTs involving 670 participants were included. Meta-analyses indicated that RS2 supplementation significantly reduced serum triacylglycerol concentrations (mean difference (MD) = −0.10 mmol/L; 95{\%} CI −0.19, −0.01, P = 0.03) in healthy individuals (n = 269) and reduced body weight (MD = −1.29 kg; 95{\%} CI −2.40, −0.17, P = 0.02) in people with T2DM (n = 90). However, these outcomes were heavily influenced by positive results from a small number of individual studies which contradicted the conclusions of the majority of trials. RS2 had no effects on any other metabolic outcomes. All studies ranged from 1–12 weeks in duration and contained small sample sizes (10–60 participants), and most had an unclear risk of bias. Short-term RS2 supplementation in humans is of limited cardiometabolic benefit.",
keywords = "Dietary fiber, Metabolic health, Metabolic syndrome, Obesity, Resistant starch, Systematic review, Type 2 diabetes",
author = "Matthew Snelson and Jessica Jong and Deanna Manolas and Smonda Kok and Audrey Louise and Romi Stern and Kellow, {Nicole J.}",
year = "2019",
month = "8",
day = "1",
doi = "10.3390/nu11081833",
language = "English",
volume = "11",
journal = "Nutrients",
issn = "2072-6643",
publisher = "MDPI",
number = "8",

}

Metabolic effects of resistant starch type 2 : A systematic literature review and meta-analysis of randomized controlled trials. / Snelson, Matthew; Jong, Jessica; Manolas, Deanna; Kok, Smonda; Louise, Audrey; Stern, Romi; Kellow, Nicole J.

In: Nutrients, Vol. 11, No. 8, 1833, 01.08.2019.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Metabolic effects of resistant starch type 2

T2 - A systematic literature review and meta-analysis of randomized controlled trials

AU - Snelson, Matthew

AU - Jong, Jessica

AU - Manolas, Deanna

AU - Kok, Smonda

AU - Louise, Audrey

AU - Stern, Romi

AU - Kellow, Nicole J.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Published evidence exploring the effects of dietary resistant starch (RS) on human cardiometabolic health is inconsistent. This review aimed to investigate the effect of dietary RS type 2 (RS2) supplementation on body weight, satiety ratings, fasting plasma glucose, glycated hemoglobin (HbA1c), insulin resistance and lipid levels in healthy individuals and those with overweight/obesity, the metabolic syndrome (MetS), prediabetes or type 2 diabetes mellitus (T2DM). Five electronic databases were searched for randomized controlled trials (RCTs) published in English between 1982 and 2018, with trials eligible for inclusion if they reported RCTs involving humans where at least one group consumed ≥ 8 g of RS2 per day and measured body weight, satiety, glucose and/or lipid metabolic outcomes. Twenty-two RCTs involving 670 participants were included. Meta-analyses indicated that RS2 supplementation significantly reduced serum triacylglycerol concentrations (mean difference (MD) = −0.10 mmol/L; 95% CI −0.19, −0.01, P = 0.03) in healthy individuals (n = 269) and reduced body weight (MD = −1.29 kg; 95% CI −2.40, −0.17, P = 0.02) in people with T2DM (n = 90). However, these outcomes were heavily influenced by positive results from a small number of individual studies which contradicted the conclusions of the majority of trials. RS2 had no effects on any other metabolic outcomes. All studies ranged from 1–12 weeks in duration and contained small sample sizes (10–60 participants), and most had an unclear risk of bias. Short-term RS2 supplementation in humans is of limited cardiometabolic benefit.

AB - Published evidence exploring the effects of dietary resistant starch (RS) on human cardiometabolic health is inconsistent. This review aimed to investigate the effect of dietary RS type 2 (RS2) supplementation on body weight, satiety ratings, fasting plasma glucose, glycated hemoglobin (HbA1c), insulin resistance and lipid levels in healthy individuals and those with overweight/obesity, the metabolic syndrome (MetS), prediabetes or type 2 diabetes mellitus (T2DM). Five electronic databases were searched for randomized controlled trials (RCTs) published in English between 1982 and 2018, with trials eligible for inclusion if they reported RCTs involving humans where at least one group consumed ≥ 8 g of RS2 per day and measured body weight, satiety, glucose and/or lipid metabolic outcomes. Twenty-two RCTs involving 670 participants were included. Meta-analyses indicated that RS2 supplementation significantly reduced serum triacylglycerol concentrations (mean difference (MD) = −0.10 mmol/L; 95% CI −0.19, −0.01, P = 0.03) in healthy individuals (n = 269) and reduced body weight (MD = −1.29 kg; 95% CI −2.40, −0.17, P = 0.02) in people with T2DM (n = 90). However, these outcomes were heavily influenced by positive results from a small number of individual studies which contradicted the conclusions of the majority of trials. RS2 had no effects on any other metabolic outcomes. All studies ranged from 1–12 weeks in duration and contained small sample sizes (10–60 participants), and most had an unclear risk of bias. Short-term RS2 supplementation in humans is of limited cardiometabolic benefit.

KW - Dietary fiber

KW - Metabolic health

KW - Metabolic syndrome

KW - Obesity

KW - Resistant starch

KW - Systematic review

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85070993824&partnerID=8YFLogxK

U2 - 10.3390/nu11081833

DO - 10.3390/nu11081833

M3 - Review Article

VL - 11

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 8

M1 - 1833

ER -